Results 201 to 210 of about 293,399 (308)

Microvascular ultrasonography for quantitative evaluation of nailfold vasculature in systemic sclerosis. [PDF]

open access: yesBMC Med Imaging
Kılıç ACK   +11 more
europepmc   +1 more source

Expert Perspectives: Defining and managing progressive pulmonary fibrosis in systemic sclerosis

open access: yesArthritis &Rheumatology, Accepted Article.
‐‐
Devis Benfaremo   +7 more
wiley   +1 more source

Human Fibroblast‐Myeloid cell tissue atlas across lung, synovium, skin and heart

open access: yesArthritis &Rheumatology, Accepted Article.
Background The availability of single‐cell RNA sequencing (scRNAseq data) in different tissues and disease states provides an opportunity to compare cellular subsets and identify common and unique cellular activation. In this study, we aimed to characterize shared and tissue‐specific myeloid and stromal phenotypes and to uncover key cellular subtypes ...
Lucy MacDonald   +9 more
wiley   +1 more source

Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis. [PDF]

open access: yesJ Scleroderma Relat Disord
Valenzuela A   +12 more
europepmc   +1 more source

Surgical Technique for Treating Focal Osteochondral Knee Lesions Using an Aragonite‐Based Biphasic Scaffold

open access: yesArthroscopy Techniques, EarlyView.
Abstract Osteochondral lesions of the knee, particularly in patients with early osteoarthritic changes, remain a clinical challenge. The Agili‐C implant (CartiHeal, Smith & Nephew), an aragonite‐based osteochondral scaffold, offers a single‐stage, off‐the‐shelf solution designed to regenerate both cartilage and subchondral bone.
Eric Wang   +4 more
wiley   +1 more source

When the Body Hardens and the Mind Fragments: Psychosis in Systemic Sclerosis. [PDF]

open access: yesCureus
Pacheco Ortega GA   +3 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort. [PDF]

open access: yesJ Scleroderma Relat Disord
Foeldvari I   +49 more
europepmc   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

open access: yesBMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo   +9 more
wiley   +1 more source

Assessment of the effectiveness of two-year rehabilitation on the functioning of patients with systemic sclerosis. [PDF]

open access: yesPostepy Dermatol Alergol
Łuczak J   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy